Trial Profile
A Randomized, Double-blind, Cross-over Study to Determine the Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980 in Previously Treated Patients With Severe Hemophilia A
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Octocog alfa (Primary)
- Indications Haemophilia A
- Focus Pharmacokinetics
- Sponsors Bayer
- 21 May 2014 New trial record